Free shipping over €250 · Tracked, discreet delivery in Europe

Actin-sequestering peptide

Thymosin beta-4

RGN-259

In clinical trialsNot yet reviewedPeptide

In short: The full 43-residue protein that TB-500 is based on. Studied in clinical trials for dry eye and slow-healing wounds.

Regulatory status

  1. Cosmetic ingredient
  2. Research compound
  3. In clinical trials
  4. Approved medicine

In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Common questions

Is Thymosin beta-4 an approved medicine?

In clinical trials. In human clinical trials and not yet approved by the FDA or the EMA. Results to date are from trial populations under medical supervision.

How much human research is there on Thymosin beta-4?

A full research summary for this compound has not been published in the library yet. The status and class above are current.

Does UU supply Thymosin beta-4?

No. It appears in the library for reference only, so the field can be read in one place.

More in Muscle, bone & joint

Back to the library
  • Cosmeticuu

    GHK-Cu

    Copper tripeptide

    Mixed evidence
  • Researchuu

    SLU-PP-332

    ERR agonist

    Preclinical
  • Researchuu

    IGF-1 LR3

    IGF-1 analogue

    Preclinical
  • Researchuu

    BPC-157

    Gastric pentadecapeptide

    Preclinical
  • Researchuu

    TB-500

    Thymosin beta-4 related peptide

    Mixed evidence
  • Approveduu

    SS-31

    Mitochondria-targeted tetrapeptide

    Human trials

The UU library is an educational reference. It is not medical advice, does not make a health claim, and does not tell anyone how to use a compound. UU products are sold for laboratory research use only and are not for human consumption. Regulatory status changes: confirm it with the relevant authority before relying on it.